{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T09:19:09Z","timestamp":1787649549364,"version":"build-2736575974"},"reference-count":40,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Foundation of Eradicate Duchenne"},{"id":[{"id":"https:\/\/ror.org\/0587jcv93","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Proteomes"],"abstract":"<jats:p>Background: Beckers muscular dystrophy (BMD) is a clinically heterogeneous dystrophinopathy caused by in-frame mutations in the dystrophin gene, resulting in variable disease severity. This variability limits the effectiveness of standardized functional measures for tracking progression. Circulating biomarkers, including urinary titin fragments generated during muscle injury, offer a promising non-invasive approach for assessing disease status. Methods: Mass spectrometry-based urinary proteomic profiling identified titin fragments as candidate biomarkers of muscle injury in BMD. These titin fragments were validated by two independent methods, targeted mass spectrometry and ELISA, using subsets of ambulatory BMD, non-ambulatory BMD and age matched healthy volunteers. Results: Urinary titin levels were significantly elevated by 4.56-fold and 2.32-fold in ambulatory and non-ambulatory BMD patients, respectively, compared with healthy controls. Titin levels also distinguished ambulatory from non-ambulatory BMD patients, demonstrating potential utility for monitoring disease progression and therapeutic response. Conclusions: Urinary titin fragments represent a promising non-invasive biomarker for BMD, with potential applicability to related neuromuscular disorders and clinical trials evaluating disease progression and treatment efficacy.<\/jats:p>","DOI":"10.3390\/proteomes14030043","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:00:48Z","timestamp":1787644848000},"page":"43","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Urinary Proteome Profiling by Several Methods Identifies Titin as the Most-Differentiating Noninvasive Urinary Biomarker of Disease Severity in Becker Muscular Dystrophy"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6478-0478","authenticated-orcid":false,"given":"Kimchi K.","family":"Le","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University\u2014SUNY, Binghamton, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9200-8294","authenticated-orcid":false,"given":"Emily H.","family":"Canessa","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University\u2014SUNY, Binghamton, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrine M.","family":"Stahura","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University\u2014SUNY, Binghamton, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Mayers","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University\u2014SUNY, Binghamton, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8826-7863","authenticated-orcid":false,"given":"Katie A.","family":"Edwards","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University\u2014SUNY, Binghamton, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University\u2014SUNY, Binghamton, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University\u2014SUNY, Binghamton, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7549-0476","authenticated-orcid":false,"given":"Yetrib","family":"Hathout","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Binghamton University\u2014SUNY, Binghamton, NY 13790, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"key":"ref_1","unstructured":"Thada, P.K., Bhandari, J., Forshaw, K.C., and Umapathi, K.K. (2026, March 14). Becker Muscular Dystrophy, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556092\/."},{"key":"ref_2","first-page":"54","article-title":"Exploring the molecular basis for variability among patients with Becker muscular dystrophy: Dystrophin gene and protein studies","volume":"49","author":"Beggs","year":"1991","journal-title":"Am. J. Hum. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/WCO.0000000000001191","article-title":"An update on Becker muscular dystrophy","volume":"36","author":"Straub","year":"2023","journal-title":"Curr. Opin. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.nmd.2024.04.004","article-title":"Long-term clinical follow-up of a family with Becker muscular dystrophy associated with a large deletion in the DMD gene","volume":"39","author":"Davies","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e16282","DOI":"10.1111\/ene.16282","article-title":"Lessons for future clinical trials in adults with Becker muscular dystrophy: Disease progression detected by muscle magnetic resonance imaging, clinical and patient-reported outcome measures","volume":"31","author":"Iterbeke","year":"2024","journal-title":"Eur. J. Neurol."},{"key":"ref_6","first-page":"e975","article-title":"Longitudinal Assessment of Creatine Kinase, Creatine\/Creatinineratio, and Myostatin as Monitoring Biomarkers in Becker Muscular Dystrophy","volume":"100","author":"Koeks","year":"2023","journal-title":"Neurology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1038\/s41598-025-85369-5","article-title":"Titin fragment is a sensitive biomarker in Duchenne muscular dystrophy model mice carrying full-length human dystrophin gene on human artificial chromosome","volume":"15","author":"Hiramuki","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/mus.27342","article-title":"Biomarkers in Duchenne and Becker muscular dystrophies","volume":"64","author":"McMillan","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1591748","DOI":"10.3389\/fneur.2025.1591748","article-title":"Serum titin\/creatinine ratio as a biomarker for discriminating disease severity in Duchenne and Becker muscular dystrophies","volume":"16","author":"Nambu","year":"2025","journal-title":"Front. Neurol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.nmd.2014.03.012","article-title":"Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy","volume":"24","author":"Rouillon","year":"2014","journal-title":"Neuromuscul. Disord."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.cca.2017.11.024","article-title":"Diagnostic and clinical significance of the titin fragment in urine of Duchenne muscular dystrophy patients","volume":"476","author":"Awano","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Sipos, A., Ripsz\u00e1m, E.R., Moln\u00e1r, J.M., Grosz, Z., Bocz\u00e1n, J., Altorjay, M.B., D\u00e9zsi, L., Cs\u00e1ti, A., Babarczy, K., and Kov\u00e1cs, N. (2025). Elevated Urinary Titin in Adult Spinal Muscular Atrophy: A Multicenter, Cross-Sectional Observational Study. Neurol. Int., 17.","DOI":"10.3390\/neurolint17080114"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/mus.27917","article-title":"Urinary titin in myotonic dystrophy type 1","volume":"68","author":"Varga","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2021.01.005","article-title":"Urinary titin as a biomarker in Fukuyama congenital muscular dystrophy","volume":"31","author":"Sato","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40618-024-02490-4","article-title":"Urinary titin as a biomarker of sarcopenia in diabetes: A propensity score matching analysis","volume":"48","author":"Takiguchi","year":"2025","journal-title":"J. Endocrinol. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"105561","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105561","article-title":"Elevated Urinary Titin and its Associated Clinical Outcomes after Acute Stroke","volume":"30","author":"Ishihara","year":"2021","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1136\/jnnp-2020-324615","article-title":"Ratio of urinary N-terminal titin fragment to urinary creatinine is a novel biomarker for amyotrophic lateral sclerosis","volume":"92","author":"Yamada","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Nakanishi, N., Tsutsumi, R., Hara, K., Matsuo, M., Sakaue, H., and Oto, J. (2021). Urinary titin N-Fragment as a biomarker of muscle atrophy, intensive care Unit-Acquired weakness, and possible application for Post-Intensive care syndrome. J. Clin. Med., 10.","DOI":"10.3390\/jcm10040614"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13395-023-00334-y","article-title":"N-terminal titin fragment: A non-invasive, pharmacodynamic biomarker for microdystrophin efficacy","volume":"14","author":"Boehler","year":"2024","journal-title":"Skelet. Muscle"},{"key":"ref_20","first-page":"840518","article-title":"Mass spectrometry-based label-free quantitative proteomics","volume":"2010","author":"Zhu","year":"2010","journal-title":"BioMed Res. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/2044-5040-1-34","article-title":"Immortalized pathological human myoblasts: Towards a universal tool for the study of neuromuscular disorders","volume":"1","author":"Mamchaoui","year":"2011","journal-title":"Skelet. Muscle"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e4437","DOI":"10.1002\/jms.4437","article-title":"Absolute quantification of dystrophin protein in human muscle biopsies using parallel reaction monitoring (PRM)","volume":"55","author":"Canessa","year":"2020","journal-title":"J. Mass Spectrom."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"39375","DOI":"10.1038\/srep39375","article-title":"Establishment of a highly sensitive sandwich ELISA for the N-terminal fragment of titin in urine","volume":"6","author":"Maruyama","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"141856","DOI":"10.1155\/2015\/141856","article-title":"Serum creatinine level: A supplemental index to distinguish Duchenne muscular dystrophy from Becker muscular dystrophy","volume":"2015","author":"Zhang","year":"2015","journal-title":"Dis. Markers"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/nmeth.1714","article-title":"MS3 eliminates ratio distortion in isobaric multiplexed quantitative proteomics","volume":"8","author":"Ting","year":"2011","journal-title":"Nat. Methods"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fcvm.2016.00021","article-title":"A Review of the Giant Protein Titin in Clinical Molecular Diagnostics of Cardiomyopathies","volume":"3","author":"Gigli","year":"2016","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1093\/hmg\/ddv116","article-title":"CAPN3-mediated processing of C-terminal titin replaced by pathological cleavage in titinopathy","volume":"24","author":"Charton","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/mus.28340","article-title":"The N-Terminal Fragment of Urine Titin Is Not a Product of Degradation by Calpain 3","volume":"71","author":"Nambu","year":"2025","journal-title":"Muscle Nerve"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1002\/jcsm.13357","article-title":"Appendicular lean mass index changes in patients with Duchenne muscular dystrophy and Becker muscular dystrophy","volume":"14","author":"Wong","year":"2023","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/jcsm.13171","article-title":"The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45-47","volume":"14","author":"Heier","year":"2023","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"dmm050595","DOI":"10.1242\/dmm.050595","article-title":"Generation and characterization of a mouse model of Becker muscular dystrophy with a deletion of Dmd exons 52 to 55","volume":"18","author":"Perillat","year":"2025","journal-title":"Dis. Model Mech."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"RP100665","DOI":"10.7554\/eLife.100665.3","article-title":"Becker muscular dystrophy mice showed site-specific decay of type IIa fibers with capillary change in skeletal muscle","volume":"13","author":"Miyazaki","year":"2025","journal-title":"eLife"},{"key":"ref_33","first-page":"149","article-title":"The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: Considerations for the design of clinical trials","volume":"87","author":"Ricotti","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.nmd.2017.05.009","article-title":"Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents","volume":"27","author":"Robertson","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Mancuso, R., Citterio, L.A., Agostini, S., Miglioli, R., Nuzzi, R., Antolini, L., Trecate, F., and Clerici, M. (2025). Circulatory titin and miR-451a are possible sarcopenia biomarkers in elderly people. Front. Aging, 6.","DOI":"10.3389\/fragi.2025.1587438"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/22143602251323629","article-title":"Urinary N-terminal titin fragment ascertained as biomarker in a small cohort of limb-girdle muscular dystrophy LGMDR1-calpain 3 related","volume":"12","author":"Valls","year":"2025","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1093\/rheumatology\/kead109","article-title":"The diagnostic value of urinary N-terminal fragment of titin for skeletal muscle damage in idiopathic inflammatory myopathy","volume":"62","author":"Sun","year":"2023","journal-title":"Rheumatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.amjcard.2018.01.046","article-title":"Usefulness of Urinary N-Terminal Fragment of Titin to Predict Mortality in Dilated Cardiomyopathy","volume":"121","author":"Yoshihisa","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.nmd.2023.02.003","article-title":"Urine titin as a novel biomarker for Duchenne muscular dystrophy","volume":"33","author":"Ishii","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10974-025-09710-1","article-title":"Urinary titin represents an exciting biomarker for assessment of muscle health","volume":"46","author":"Melisi","year":"2025","journal-title":"J. Muscle Res. Cell Motil."}],"container-title":["Proteomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-7382\/14\/3\/43\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T08:24:26Z","timestamp":1787646266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-7382\/14\/3\/43"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["proteomes14030043"],"URL":"https:\/\/doi.org\/10.3390\/proteomes14030043","relation":{},"ISSN":["2227-7382"],"issn-type":[{"value":"2227-7382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}